Hodeib Hossam, Hagras Maha M, Abdelhai Dina, Watany Mona M, Selim Amal, Tawfik Mohamed A, Elsebaey Mohamed A, Elshweikh Samah A
Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt,
Diabetes Metab Syndr Obes. 2019 Mar 13;12:325-331. doi: 10.2147/DMSO.S194410. eCollection 2019.
Diabetic nephropathy (DN) represents one of the main causes of end-stage renal disease in type 2 diabetes mellitus (DM) patients. Galectin-3 has been implicated in pathogenesis of many pathological conditions. To date, there are limited data regarding the relationship between galectin-3 and DN.
Evaluation of serum galectin-3 as a novel prognostic biomarker in patients with DN.
This prospective study was carried out in the Internal Medicine and Clinical Pathology Departments, Tanta University Hospital, Egypt, from March 2015 to March 2018 on 300 patients with type 2 DM. Patients were divided into three groups: group I included 100 patients with albumin/creatinine ratio (ACR) <30 mg/g (normoalbuminuria), group II included 100 patients with ACR within 30-300 mg/g (microalbuminuria), and group III included 100 patients with ACR >300 mg/g (macroalbuminuria). All patients were subjected to the following: full history taking, clinical examination, and laboratory evaluation (HbA1c, creatinine, estimated glomerular filtration rate, ACR, and serum galectin-3).
The mean levels of galectin-3 were significantly higher in patients with macroalbuminuria than in those with microalbuminuria and normoalbuminuria. Galectin-3 was a significant predictor for progression to microalbuminuria, macroalbuminuria, dialysis, and death among patients with type 2 DM.
Based on this single center prospective study, serum galectin-3 is considered a significant predictor for DN progression among patients with type 2 DM.
糖尿病肾病（DN）是2型糖尿病（DM）患者终末期肾病的主要病因之一。半乳糖凝集素-3与许多病理状况的发病机制有关。迄今为止，关于半乳糖凝集素-3与DN之间关系的数据有限。
评估血清半乳糖凝集素-3作为DN患者一种新的预后生物标志物。
这项前瞻性研究于2015年3月至2018年3月在埃及坦塔大学医院内科和临床病理科对300例2型糖尿病患者进行。患者分为三组：第一组包括100例白蛋白/肌酐比值（ACR）<30mg/g（正常白蛋白尿）的患者，第二组包括100例ACR在30 - 300mg/g之间（微量白蛋白尿）的患者，第三组包括100例ACR>300mg/g（大量白蛋白尿）的患者。所有患者均接受以下检查：详细病史采集、临床检查和实验室评估（糖化血红蛋白、肌酐、估计肾小球滤过率、ACR和血清半乳糖凝集素-3）。
大量白蛋白尿患者的半乳糖凝集素-3平均水平显著高于微量白蛋白尿和正常白蛋白尿患者。半乳糖凝集素-3是2型糖尿病患者进展为微量白蛋白尿、大量白蛋白尿、透析和死亡的重要预测指标。
基于这项单中心前瞻性研究，血清半乳糖凝集素-3被认为是2型糖尿病患者DN进展的重要预测指标。
